DNA Damage Repair Genes in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Implications- A Narrative Review.

Authors

Ana-Karla Durán-Toribio, Ignacio F Jiménez-Díaz, Enrique Caballé-Pérez, José Lucio-Lozada, Cesar Castillo-Ruiz, Pedro Barrios-Bernal, Eunice Romero-Núñez, Norma Hernández-Pedro, Oscar Arrieta

Published in

Critical reviews in oncology/hematology. Pages 105546. Aug 15, 2026. Epub Aug 15, 2026.

Abstract

Lung cancer management remains constrained by a fragmented understanding of the clinical implications of DNA Damage Response (DDR) pathways. This review synthesizes current evidence to position DDR alterations as potential prognostic, predictive, and therapeutic biomarkers. Prognostically, overexpression of FEN1, BRCA1, and XRCC4/5/6 correlates with poor survival in non-small cell lung cancer, whereas low ERCC1 expression and specific EXO1 or RPA polymorphisms are associated with enhanced responsiveness to platinum-based chemotherapy. As well, deleterious mutations in ATM, ERCC family genes, and mismatch repair genes (MSH2, PMS2) may support the identification of patients more likely to benefit from immune checkpoint inhibitors, driven by increased tumor mutational burden and neoantigen load. Therapeutically, PARP and ATR inhibitors may offer an opportunity within precision strategies through synthetic lethality, with particular promise in difficult-to-treat subsets, including KRAS-mutated adenocarcinoma and patients progressing on standard targeted therapies. However, clinical implementation faces significant technical limitations regarding testing variability (particularly isoform specificity), geographic biases toward Asian populations, and severe overlapping toxicities in combination trials. To facilitate the integration of DDR biomarkers into routine practice, future research must prioritize assay standardization, broader ethnic representation, and mechanistic exploration of DDR-mediated remodeling of the tumor microenvironment. Integrating these complex molecular interactions is essential to bridge the gap between biological activity and personalized clinical application in lung cancer.

PMID:
42603641
Bibliographic data and abstract were imported from PubMed on 16 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.